Explore the Diagnostic Efficiency of Chinese Thyroid Imaging Reporting and Data Systems by Comparing With the Other Four Systems (ACR TI-RADS, Kwak-TIRADS, KSThR-TIRADS, and EU-TIRADS): A Single-Center Study

Qi Qi†, Aiyun Zhou†, Suping Guo, Xingzi Huang, Songli Chen, Yaohui Li and Pan Xu*

Department of Ultrasonography, The First Affiliated Hospital of Nanchang University, Nanchang, China

Purpose: To explore the characteristics of C-TIRADS by comparing it with ACR-TIRADS, Kwak-TIRADS, KSThR-TIRADS and EU-TIRADS.

Methods: A total of 1096 nodules were collected from 884 patients undergoing thyroidectomy in our center between May 2018 and December 2020. Divided the nodules into two groups: “>10mm” and “≤10mm”. Ultrasound characteristics of each nodule were observed and recorded by 2 doctors, then classified based on ACR-TIRADS, Kwak-TIRADS, KSThR-TIRADS, EU-TIRADS, and C-TIRADS.

Results: A total of 682 benign nodules cases (62.23%) and 414 malignant nodules cases (37.77%) were identified. The ICC value of each guideline was: 0.937(ACR-TIRADS), 0.858(EU-IRADS), 0.811(Kwak-TIRADS), 0.835(KTA/KSThR-TIRADS) and 0.854(C-TIRADS). The nodule malignancy rates in the groups(Kwak-TIRADS 4B, C-TIRADS 4B、4C) of two sizes were significantly different (all p<0.05). There was no statistical difference in the other grades of two sizes (all p>0.05). Unnecessary biopsy rates were the lowest in C-TIRADS (49.02% p<0.001). Furthermore, Kwak-TIRADS had the highest sensitivity and NPV (89.9%, 91.0%, all p<0.05), while C-TIRADS had the highest specificity and PPV (82.3%, 69.2%, all p<0.05). C-TIRADS and Kwak-TIRADS had the highest accuracy (76.0%, 72.5%, P=0.071). The AUCs of the 5 guidelines were C-TIRADS(0.816, P<0.05), Kwak-TIRADS(0.789, P<0.05) KTA/KSThR-TIRADS and ACR-TIRADS(0.773, 0.763, P=0.305), EU-TIRADS(0.734, P<0.05). The AUCs of the five guidelines were not statistically different between “nodules>10mm” and “nodules ≤ 10mm” (all P>0.05).

Conclusions: All five guides showed excellent interobserver agreement. C-TIRADS was slightly efficient than Kwak-IRADS, KTA/KSThR-TIRADS and ACR-TIRADS, and had greater advantages than EU-TIRADS. The diagnostic abilities of the five guidelines for
“nodules ≤ 10mm” were not inferior to that of “nodules> 10mm”. C-TIRADS is simple and easy to implement and can provide effective thyroid tumor risk stratification for thyroid nodule diagnosis, especially in China.

Keywords: thyroid nodule, diagnostic imaging, ultrasonography, risk assessment, C-TIRADS

INTRODUCTION

Thyroid nodule is the most common thyroid gland disease. Thyroid and malignant nodules can be detected in over 50% and 7-15% of the general population, respectively (1). Ultrasound is the most commonly used and effective imaging method for thyroid nodule diagnosis. Ultrasound can show the morphological characteristics of thyroid nodules clearly, including nodules ≤10mm. The number of thyroid nodules and malignant thyroid nodules detected has been increasing yearly due to the increased use of thyroid ultrasonography. Presently, various guidelines are used to differentiate benign and malignant thyroid nodules in clinical practice and science. Previous research showed that each guideline has advantages and limitations (2-8).

The following guidelines are widely used in China: Kwak-TIRADS (Thyroid Imaging Reporting and Data System) developed by Kwak and published in Radiology in 2011 (9), KTA/KSThR-TIRADS developed by the Korean Society of Radiology and the Korean Society of Thyroid Radiology in 2016 (10), ACR-TIRADS guideline, developed by the American College of Radiology in 2017 (ACR) (11), and EU-TIRADS created by European Thyroid Association (2017) (ETA) (12). The above guidelines are used to detect malignant probability based on the ultrasound characteristics of thyroid nodules to guide further treatment. These guidelines indicate similar suspicious features of thyroid nodules, such as solid, hypoechoic, marked hypoechoic, irregular margin, and microcalcification. However, the specific ultrasound characteristics, counting, and grading methods are different FNA (fine needle aspiration) recommendations are also different (12).

The use of TIRADS guidelines in China is not yet uniform and can cause doubts to clinicians and patients (13). Furthermore, ultrasound doctors face some challenges during diagnosis. For instance, ACR-TIRADS assigns scores to about 18 ultrasound features, which is ineffective for diagnosis and can reduce the efficiency of diagnosis in a country with a large population. The malignancy rates of the highest grades of ACR-TIRADS and EU-TIRADS are >20% and 26%-87%, respectively, the malignant rates range corresponding to the highest grades were too large, which confusing clinicians on the treatment of thyroid nodules. One more malignant feature can make the classification reach 4C and 5 when using Kwak-TIRADS and EU-TIRADS guidelines for solid hypoechoic nodules. These TIRADS guidelines also guide FNA. However, it is not realistic to conduct FNA before determining every treatment plan in China since it is not widely developed in China.

The Superficial Organ and Vascular Ultrasound Group in the Chinese Medical Association issued a new guideline, C-TIRADS (Chinese Thyroid Imaging Reporting and Data Systems), in August 2020 to solve the above problems (13). C-TIRADS is a new counting classification method used for thyroid nodule diagnosis and guiding thyroid FNA. It takes into account both the international standards and China’s national conditions. Presently, few studies have reported on C-TIRADS. This study aimed to explore the characteristics of C-TIRADS by comparing it with ACR-TIRADS, Kwak-TIRADS, KSThR-TIRADS and EU-TIRADS.

MATERIALS AND METHODS

This is a retrospective study. Informed consent was not required for this retrospective observational study.

Patient Selection

From May 2018 to December 2020, two radiologists with over 5 and 7 years of experience in thyroid ultrasound diagnosis collected ultrasound images of 2683 consecutive patients with 3524 thyroid nodules in our hospital. The patients were followed up, except for pregnant and breastfeeding women and patients with a thyroid surgery history. Finally, 884 patients (1096 nodules) who underwent thyroidectomy (complete, almost complete, or unilateral thyroidectomy), had complete clinical data such as gender and age, ultrasound features data and surgical pathological results of thyroid nodules were included in the study (Figure 1).

Thyroid Ultrasound Examination

All ultrasound examinations were performed with Phillip iu22, epiq7 or Toshiba apio6050 devices equipped with either a 5–12 MHz or a 10 MHz linear-array transducer. Two US experts who had 5 and 7 years of experience in performing thyroid US examination explored the thyroid region of the patients, stored the complete and clear thyroid nodules ultrasound images as JPEG files, recorded the location of the nodules (right/left lobe, isthmus), the three diameters of the nodes were measured three times and the average value was recorded. The three diameters of the nodes (upper and lower diameter, left and right diameter, front and back diameter) were measured three times and the average values were recorded. Recorded the maximum diameter of the nodules. Suspicious cervical lymph node metastasis was also observed.

Nodule Analysis

The nodules without histological results were excluded after follow-up. Two US experts who had 10 and 15 years of experience in performing thyroid US examination and did not
know the final histology of nodules retrospectively reviewed the images and independently analyzed all nodules. Only the nodules with clear pathological diagnoses were included when a patient had more than one nodule. Nodule composition (cystic, almost completely cystic, spongiform, mixed cystic and solid, solid or almost completely solid), echogenicity (no echo, hyperechoic, isoecho, hypoechoic, markedly hypoechoic), shape (wider-than-tall, taller-than-wide), Margin (well circumscribed, microlobulated or irregular, ill-defined, extra thyroid extension), and hyperechoic (microcalciﬁcations, peripheral calcification, macrocalciﬁcations, comet-tail sign) were recorded. The nodules were then classiﬁed based on Kwak-TIRADS (9), KSThR-TIRADS (10), ACR-TIRADS (11), EU-TIRADS (12), and C-TIRADS (2) guidelines. The results were compared, and the two doctors discussed and settled on a ﬁnal result whenever there was a disagreement.

Statistics
IBM SPSS Statistics (version 22) and R-Project (version 4.0.5) were used for statistical analyses. Quantitative data were presented as mean ± standard deviation (SD), while qualitative data were presented as frequencies. The Shapiro–Wilk test was used to determine the presence of a normal distribution. Differences between groups were analyzed using a Mann–Whitney U test for nonparametric data and an unpaired t-test for parametric data. The χ2 test or Fisher’s exact test was used to compare categorical variables. ICC (intraclass correlation coefﬁcient) was used to evaluate inter-observer agreement. Unnecessary biopsy rates were calculated as the proportion of benign nodules among thyroid nodules that were indicated for biopsy in the ﬁve guidelines. The sensitivity, speciﬁcity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were determined by comparing them with the pathological ﬁndings. Kendall’s tau-b test was used to assess the relationship between each category and the pathology ﬁndings. The receiver operating characteristic (ROC) curves of the four guidelines were used to calculate the best cut-off value. The DeLong test was used to compare the ROC curves via the pROC software package ("R-Project, version 4.0.5"). P < 0.05 was considered statistically significant.

RESULTS
Characteristics of Patients and Nodules
A total of 884 patients (681 females and 203 males; median age, 43.91 years; between 10 and 78 years) were included in the study. A total of 507 benign cases (397 females and 110 males; median age, 49.26 years; between 25 and 78 years) and 377 malignant cases (284 females and 93 males; median age, 41.83 years; between 10 and 73 years) were detected. Patients with thyroid cancer were signiﬁcantly younger than those with benign nodules (P<0.001). The gender difference was not signiﬁcant (P=0.299).

A total of 1096 thyroid nodules (average maximum diameter, 18.86 mm, between 5 and 64 mm) were identiﬁed. There were 682 benign nodules (average maximum diameter, 19.13 mm between 5 and 64 mm) and 414 malignant nodules (average maximum diameter, 17.76 mm between 5 and 60 mm). The malignant nodules were smaller than the benign nodules (P=0.043). The pathological results of the nodules are shown in Table 1.

FNA was performed on 332 nodules (248 malignant nodes and 75 benign nodes). 7 nodules were classiﬁed as BSRTC I, 58 as BSRTC II, 12 as BSRTC III, 12 as BSRTC IV, 104 as BSRTC V, and 139 as BSRTC VI.

The Relationship Between the Classiﬁcation of the Five Guidelines and Nodule Pathology
The incidence of malignancies of different grades in the five guidelines is shown in Table 2. The calculated malignancy rates of the following levels were higher than the recommended
malignancy risks: ACR-TIRADS TR3 11.48% (2%-5%), ACR-TIRADS TR4 29.24% (5%-20%), EU-TIRADS4 22.86% (6%-17%), C-TIRADS4A 16.77% (2%-10%), and the calculated malignancy rate so within the recommended malignancy risk range. The correlation coefficients of five guidelines were: 0.442 (ACR-TIRADS), 0.502 (Kwak-TIRADS), 0.427 (EU-TIRADS), 0.502 (C-TIRADS), 0.467 (KTA/KSThR-TIRADS).

Each guideline was divided into groups according to whether the nodule was greater or smaller than 10mm. The number of nodules and the incidence of malignant tumors in each group were calculated (Table 2). The nodule malignancy rates in the grades (Kwak-TIRADS 4B, C-TIRADS 4B, C-TIRADS 4C) of two sizes were significantly different (all p<0.05). And the malignancy rates of Kwak-TIRADS 4B were higher in “nodules ≤10mm” than in “nodules >10mm”. The malignancy rates of C-TIRADS 4B and C-TIRADS 4C were lower in “nodules ≤10mm” than in “nodules >10mm”. There was no statistical difference in the malignant rate of nodules in the other grades between “nodules ≤10mm” and “ nodules >10mm” (all P>0.05).

Inter-Observer Agreement
Consistency analysis was conducted for the original data of the two doctors. The ICC value of each guideline was: 0.937 (ACR-TIRADS), 0.858 (EU-TIRADS), 0.811 (Kwak-TIRADS), 0.835 (KTA/KSThR-TIRADS) and 0.854 (C-TIRADS), with good repeatability (Figure 2). The ICC value of each US feature was: 0.867 (composition), 0.758 (echogenicity), 0.726 (hyperechoic), 0.799 (margin), 0.726 (shape), with good repeatability (Figure 3).

Unnecessary Biopsy Rate
Supplementary Material 2 shows statistics on the FNA recommended by each guideline. If FNA was performed on each nodule that met the FNA indication in this study, their

| Pathology | n (%) |
|-----------|-------|
| Benign    | 682 (62.23%) |
| Nodular goiter | 473 (89.35%) |
| Normal follicular cells | 17 (2.49%) |
| Follicular adenoma | 148 (20.53%) |
| Inflammatory changes of thyroid gland | 33 (4.84%) |
| Other benign lesions | 11 (1.61%) |
| Malignant | 414 (37.77%) |
| Papillary carcinoma | 384 (92.75%) |
| follicular carcinoma | 10 (2.42%) |
| Medullary carcinoma | 7 (1.69%) |
| Undifferentiated carcinoma | 6 (1.45%) |
| Other malignant lesions | 7 (1.69%) |

### Table 1: Pathological results of 1096 thyroid nodules.

| Pathology          | n (%) |
|--------------------|-------|
| Benign             | 682 (62.23%) |
| Nodular goiter     | 473 (89.35%) |
| Normal follicular cells | 17 (2.49%) |
| Follicular adenoma | 148 (20.53%) |
| Inflammatory changes of thyroid gland | 33 (4.84%) |
| Other benign lesions | 11 (1.61%) |
| Malignant          | 414 (37.77%) |
| Papillary carcinoma | 384 (92.75%) |
| follicular carcinoma | 10 (2.42%) |
| Medullary carcinoma | 7 (1.69%) |
| Undifferentiated carcinoma | 6 (1.45%) |
| Other malignant lesions | 7 (1.69%) |

### Table 2: Malignancy rates in ACR-TIRADS, Kwak-TIRADS, EU-TIRADS, C-TIRADS, KTA/KSThR-TIRADS.

| Classification | Total (n) | CMR (%) | RMR (%) | CC | P value |
|---------------|-----------|---------|---------|----|---------|
| ACR-TIRADS    |           |         |         |    |         |
| TR1           | 40        | 0       | 40      | <2 | 0.442   |
| TR2           | 145       | 1       | 146     | <2 |         |
| TR3           | 54        | 7       | 61      | 11.48 | 2-5   |
| TR4           | 242       | 100     | 342     | 29.24 | 5-20   |
| TR5           | 201       | 306     | 507     | 60.36 | >20    |
| Kwak-TIRADS   |           |         |         |    |         |
| 2             | 40        | 0       | 40      | 0   | 0.502   |
| 3             | 149       | 1       | 150     | 0.67 | <5     |
| 4A            | 98        | 6       | 104     | 7.55 | 2-10   |
| 4B            | 136       | 33      | 169     | 19.53 | 10-50  |
| 4C            | 246       | 326     | 572     | 56.99 | 50-85  |
| 5             | 13        | 46      | 59      | 77.97 | 85-100 |
| EU-TIRADS     |           |         |         |    |         |
| 2             | 40        | 0       | 40      | 0   | 0.427   |
| 3             | 203       | 9       | 212     | 4.25 | 2-4    |
| 4             | 135       | 40      | 175     | 22.86 | 6-17   |
| 5             | 304       | 365     | 669     | 54.56 | 26-87  |
| C-TIRADS      |           |         |         |    |         |
| 2             | 44        | 0       | 44      | 0   | 0.502   |
| 3             | 137       | 28      | 165     | 16.77 | 10-50  |
| 4A            | 191       | 112     | 303     | 36.96 | 10-50  |
| 4B            | 212       | 263     | 485     | 68.49 | 50-90  |
| 5             | 0         | 9       | 9       | 100  | >90     |
| KTA/KSThR-TIRADS |       |         |         |    | <0.001 |
| 2             | 74        | 0       | 74      | <3 | 0.467   |
| 3             | 210       | 10      | 220     | 4.55 | 3-15   |
| 4             | 171       | 66      | 237     | 27.85 | 15-50  |
| 5             | 227       | 398     | 625     | 59.82 | >60    |

B, benign nodules; M, malignant nodules; TN, thyroid nodule; CMR, calculated malignancy rate; RMR, recommended malignancy risk; CC, correlation coefficient.
FIGURE 2 | The ICC values of five guidelines.

FIGURE 3 | The ICC values of Ultrasound features.
unnecessary biopsy rates are: ACR-TIRADS 50.25%, EU-TIRADS 55.99%, Kwak-TIRADS 53.09%, C-TIRADS 49.02%, KTA/KSThR-TIRADS 58.36%, (all P<0.001).

**Diagnostic Performance of the Five Guidelines**

The diagnostic efficacy and the ROC curves of the five guidelines are shown in Table 3, respectively. ROC analysis showed that the best diagnostic cut-off values of ACR-TIRADS, Kwak-TIRADS, EU-TIRADS, KTA/KSThR-TIRADS and C-TIRADS were TR5, 4C, 5 and 4C, respectively. Kwak-TIRADS had the highest sensitivity and NPV (89.9%, 91.0%, all P<0.05). C-TIRADS and Kwak-TIRADS had the highest specificity, PPV (82.3%, 69.2%, all P<0.05). C-TIRADS and Kwak-TIRADS had the highest accuracy (76.0%, 72.5%, P=0.071). Furthermore, C-TIRADS had the highest AUC (0.816, all P<0.001), followed by Kwak-TIRADS (0.79, all P<0.05). There was no statistical difference between KTA/KSThR-TIRADS and ACR-TIRADS (0.773, 0.763, P=0.305). The AUC of EU-TIRADS was 0.734 (all P<0.001).

The diagnostic efficacy of the five guidelines for nodules with different sizes is shown in Table 4. The AUCs of the five guidelines were not statistically different between “nodules ≤10mm” and “nodules >10mm” (all P>0.05).

**DISCUSSION**

Most guidelines currently provide guidance for FNA, but FNA is not widely available in China, and it is not realistic to mandate FNA for every thyroid nodule before deciding on a treatment plan. Therefore, C-TIRADS guideline points out that in medical institutions that have not yet carried out FNA, the results of C-TIRADS may provide some suggestions for surgeons' treatment decisions (13). Furthermore, Kwak-TIRADS and C-TIRADS were very similar, and both had the simplest counting method. However, C-TIRADS was different from other risk stratifications since it removed the “hypoechoic” and “mainly solid” characteristics from the malignant signs, indicating the “comet tail sign” as a benign sign and calculating it as -1 point. The Kwak-TIRADS and C-TIRADS grades of the same nodule were then compared. A total of 462 nodules were degraded due to echo and composition. For the number of high-grade nodules, a total of 393 high-grade nodules of C-TIRADS (C-TIRADS 4C+C-TIRADS 5) were identified, which was lower than EU-TIRADS 5 (669 cases), Kwak-TIRADS (631 cases) (Kwak-TIRADS4C+Kwak-TIRADS 5), KTA/KSThR-TIRADS 5 (565 cases) and ACR-TIRADS TR5 (507 cases). The unnecessary puncture rate of C-TIRADS was lowest (49.02%, all P<0.001). Therefore, C-TIRADS can reduce the grade of nodules without affecting the puncture standards.

The benign and malignant nodules had different sizes, and the maximum diameter of benign nodules was larger than that of malignant nodules, consistent with Gao’s study (14). The difference could be due to selection bias since most benign patients undergo surgery due to compressive symptoms and aesthetic needs. The malignancy rate of nodules in each guideline increased with the increase in the grade, indicating a correlation with guidelines. The malignancy rates of most grades in the 5 guidelines were within the range of malignancy rates recommended by each guideline, which shows that the sample in this study was representative. ACR-TIRADS TR3 (11.48%), ACR-TIRADS TR4 (29.24%), EU-TIRADS3 (4.25%), EU-TIRADS4 (22.86%), C-TIRADS4A (16.77%) had higher malignancy rates than the recommended range, but some were comparable to the malignancy rates reported in previous studies (14–16). The difference could be due to the deviation caused by several malignant nodules or sub-centimeter nodules and different observers. The prerequisite for a guideline to be widely used is that it has good consistency among doctors. In our study, the two doctors used the five guidelines and showed consistent results, indicating that the five guidelines can be used in a standardized manner. Regarding US features, the inter-observer agreement was slightly worse for hyperechoic (ICC, 0.726), echogenicity (ICC, 0.758) and margin (ICC, 0.799) relative to other features. The study by

| Method        | Cut-off | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) | AUC  |
|---------------|---------|----------------|----------------|---------|---------|--------------|------|
| ACR-TIRADS    | 5       | 73.9           | 70.5           | 60.4    | 81.7    | 71.8         | 0.763|
|               |         | (69.4-78.1)    | (67.0-73.9)    | (57.2-63.4) | (79.09-84.1) | (69.0-74.5) | (0.736-0.791) |
|               | P value | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | 0.439<sup>a</sup> | 0.029<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> |<0.305<sup>c</sup> |
| Kwak-TIRADS   | 4C      | 89.9           | 62.0           | 58.9    | 91.0    | 72.5         | 0.789|
|               |         | (86.5-92.6)    | (59.3-65.7)    | (66.6-61.3) | (88.3-93.1) | (68.9-75.2) | (0.763-0.815) |
|               | P value | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> |<0.001<sup>a</sup> |
| EU-TIRADS     | 5       | 88.2           | 55.4           | 54.6    | 88.5    | 67.8         | 0.734|
|               |         | (84.7-91.1)    | (51.6-59.2)    | (52.3-56.8) | (85.5-91.0) | (64.9-70.6) | (0.705-0.763) |
|               | P value | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.001<sup>a</sup> |<0.001<sup>a</sup> |<0.001<sup>a</sup> |<0.001<sup>a</sup> |
| KTA/KSThR-TIRADS | 5   | 81.6           | 66.7           | 59.8    | 85.7    | 72.4         | 0.773|
|               |         | (77.6-85.3)    | (63.0-70.3)    | (57.0-62.6) | (82.9-88.1) | (69.6-75.0) | (0.748-0.800) |
|               | P value | <0.001<sup>a</sup> | <0.001<sup>a</sup> | <0.037<sup>a</sup> | 0.708<sup>a</sup> | 0.043<sup>a</sup> | <0.001<sup>a</sup> |<0.014<sup>b</sup> |
| C-TIRADS      | 4C      | 75.7           | 82.3           | 69.2    | 79.8    | 76.0         | 0.816|
|               |         | (70.9-80.3)    | (79.2-85.1)    | (65.3-72.8) | (77.45-81.9) | (73.4-78.5) | (0.791-0.841) |
Park et al. (17) concluded that the consistency of echogenicity was poor. In a multi-center study by Persichetti et al. (18) and a single-center study by Giorgio et al. (19), hyperechoic and margin were also US features with poor interobserver agreement. A uniform lexicon of thyroid US features, simplified classification methods, and specialized training to describe thyroid US findings may improve observers’ agreement.

ROC was used to analyze the diagnostic performance of the four guidelines. First, the diagnostic cut-offs of the four guidelines, ACR-TIRADS TR5, Kwak-TIRADS 4C, KTA/KSThR-TIRADS 5, and EU-TIRADS 5 were identified, which was similar to that of Gao, Ali Murat Koc (14, 20). However, Simone indicated that the diagnostic cut-off value of ACR-TIRADS is TR4, while Du showed that the diagnostic cut-off value of Kwak-TIRADS is 4B (21, 22). They also showed that the malignancy rate of the two nodule grades is very high, possibly due to the deviations in the data source. The diagnostic cut-off value of C-TIRADS was 4C. ACR-TIRADS showed the highest specificity compared to the other three guidelines (except C-TIRADS), similar to previous findings (14, 23, 24). The above articles all compared multiple guidelines, including ACR-TIRADS and Kwak-TIRADS. This study shows that Kwak-TIRADS had the highest sensitivity. Hu et al. (25) was similar to this study. C-TIRADS had the highest specificity (82.3%), PPV (69.2%) and accuracy (76.0%). The sensitivity of C-TIRADS (75.7%) was low, the same as Zhu et al., but it was still better than ACR-TIRADS (73.9%) (26). Besides, C-TIRADS had the highest AUC (0.816, all P<0.05). Therefore, C-TIRADS has the highest diagnostic performance under the premise that each diagnostic index had no obvious shortcomings.

This study included 19.1% sub-centimeter nodules. Most guidelines recommend using an active monitoring strategy instead of surgical treatment for low-risk sub-centimeter nodule treatment. However, in China, some patients with sub-centimeter nodules (such as suspicious cervical lymph nodes, other thyroid symptoms, no active follow-up, or hope for more radical treatments) choose surgery. Furthermore, most low-grade sub-centimeter nodules were obtained with malignant nodules when the thyroid lobes were removed. However, these treatment options were controversial. Presently, few studies have reported on various diagnostic properties of sub-centimeter thyroid nodules.

Except for Kwak-TIRADS 4B, C-TIRADS 4B, and 4C, the malignancy rates were no statistical difference between “nodules ≤10mm” and “nodules <10mm” in the other grades (all P>0.05). The AUCs of the five guidelines were not statistically different between the two sizes (all P>0.05). Many studies have shown that the malignancy rate of high-grade small-size nodules is lower than that of large-size nodules. Studies have also shown that the guidelines have better diagnostic efficiency in identifying “nodules <10mm” than “nodules ≤10mm” (12, 14). However, some studies have shown that the incidence of malignant tumors increases with the number of suspicious features, regardless of the size of the nodules (27, 28). Some studies have shown that papillary thyroid microcarcinomas (PTMCs) account for 59.7% of malignant nodules and increase during follow-up (13, 29–31). At present, although the diagnostic ability of the guidelines is controversial for sub-centimeter nodules, it is clear that in our study, the diagnostic ability of the 5 guidelines for “nodules ≤10mm” is not inferior to “nodules <10mm”.

TABLE 4 | Diagnostic performance of different sizes of 5 guidelines.

| Method          | Cut-off | Sensitivity (%) | Specificity (%) | PPV (%)  | NPV (%)  | Accuracy (%) | AUC       |
|-----------------|---------|-----------------|-----------------|----------|----------|--------------|----------|
| ACR-TIRADS      | ≤10mm   | 70.4            | 68.4            | 53.2     | 81.9     | 69.1         | 0.746    |
|                 | >10mm   | 74.6            | 70.1            | 62.0     | 80.9     | 71.9         | 0.767    |
| P value         | ≤10mm   | 0.025           | 0.235           | 0.537    | 0.052    | 0.859        | 0.513    |
|                 | >10mm   | 0.025           | 0.235           | 0.537    | 0.052    | 0.859        | 0.513    |
| Kwak-TIRADS     | ≤10mm   | 80.3            | 63.3            | 52.8     | 86.3     | 69.1         | 0.780    |
|                 | >10mm   | 91.8            | 61.7            | 60.2     | 92.3     | 73.4         | 0.790    |
| P value         | ≤10mm   | 0.007           | 0.801           | 0.185    | 0.094    | 0.240        | 0.721    |
|                 | >10mm   | 0.007           | 0.801           | 0.185    | 0.094    | 0.240        | 0.721    |
| EU-TIRADS       | ≤10mm   | 77.5            | 60.4            | 50.0     | 84.0     | 66.2         | 0.726    |
|                 | >10mm   | 90.3            | 54.1            | 55.5     | 89.9     | 68.2         | 0.734    |
| P value         | ≤10mm   | 0.004           | 0.216           | 0.344    | 0.149    | 0.838        | 0.784    |
|                 | >10mm   | 0.004           | 0.216           | 0.344    | 0.149    | 0.838        | 0.784    |
| C-TIRADS        | ≤10mm   | 56.8-80.7       | 69.0-97.5       | 72.3-91.4| 77.3-85.7| 76.5-87.3    | 0.776    |
|                 | >10mm   | 77.1            | 79.2            | 67.1     | 79.2     | 74.5         | 0.808    |
| P value         | ≤10mm   | 0.254           | <0.001          | 0.023    | 0.527    | 0.021        | 0.411    |
|                 | >10mm   | 0.254           | <0.001          | 0.023    | 0.527    | 0.021        | 0.411    |
| KTA/KSThR-TIRADS| ≤10mm   | 74.7            | 65.5            | 52.5     | 83.5     | 68.6         | 0.750    |
|                 | >10mm   | 83.1            | 67.0            | 61.4     | 86.3     | 73.3         | 0.779    |
| P value         | ≤10mm   | 0.132           | 0.803           | 0.121    | 0.560    | 0.201        | 0.385    |

95% confidence intervals are in parentheses; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the receiving operator characteristics curve; P value, Compared with C-TIRADS.
This research also had some limitations. First, all patients underwent thyroidectomy, increasing the proportion of malignant nodules, decreasing the number of low-grade nodules, thus increasing the number of high-grade nodules. This can cause selection bias, affecting the diagnostic efficacies of the guidelines and reducing the consistencies of diagnoses. Second, clinicians retrospectively analyzed all nodes based on static images only. Static images will affect the evaluation of ultrasonic features, especially the margin of nodules. Real-time dynamic images can evaluate ultrasonic features more accurately. Finally, this was a single-center retrospective study, with guaranteed consistencies of nodule diagnosis results. But, the heterogeneity of the patient population was smaller than that of the multi-center study.

CONCLUSIONS

All five guides showed excellent inter-observer agreement. C-TIRADS was slightly efficient than Kwak-IRADS, KTA/KSThR-TIRADS and ACR-TIRADS, and had greater advantages than EU-TIRADS. The diagnostic abilities of the five guidelines for “nodules ≤ 10mm” were not inferior to that of “nodules > 10mm”. C-TIRADS is simple and easy to implement and can provide effective thyroid tumor risk stratification for thyroid nodule diagnosis, especially in China.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

REFERENCES

1. Guth S, Thene U, Aberle J, Galach A, Bamberger CM. Very High Prevalence of Thyroid Nodules Detected by High Frequency (13 MHz) Ultrasound Examination. Eur J Clin Invest (2009) 39:699–706. doi: 10.1111/j.1365-2362.2009.02162.x
2. Ha EJ, Na DG, Baek JH, Sung JY, Kim JH, Kang SY. US Fine-Needle Aspiration Biopsy for Thyroid Malignancy: Diagnostic Performance of Seven Society Guidelines Applied to 2000 Thyroid Nodules. Radiology (2018) 287:893–900. doi: 10.1148/radiol.2018171074
3. Yoon JH, Han K, Kim EK, Moon HJ, Kwak JY. Diagnosis and Management of Small Thyroid Nodules: A Comparative Study With Six Guidelines for Thyroid Nodules. Radiology (2017) 283:560–9. doi: 10.1148/radiol.2016160641
4. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Malignancy Risk Stratification of Thyroid Nodules: Comparison Between the Thyroid Imaging Reporting and Data System and the 2014 American Thyroid Association Management Guidelines. Radiology (2016) 278:917–24. doi: 10.1148/radiol.2015150056
5. Ha SM, Ahn HS, Baek JH, Ahn HY, Chung YJ, Cho BY, et al. Validation of Three Scoring Risk-Stratification Models for Thyroid Nodules. Thyroid (2017) 27:1550–7. doi: 10.1089/thy.2017.0363
6. Yoon SJ, Na DG, Gwon HY, Paik W, Kim WJ, Song JS, et al. Similarities and Differences Between Thyroid Imaging Reporting and Data Systems. AJR Am J Roentgenol (2019) 213:W76–84. doi: 10.2214/AJR.18.20510
7. Yoon JH, Lee HS, Kim EK, Moon HJ, Park YV, Kwak JY. Pattern-Based vs. Score-Based Guidelines Using Ultrasound Features Have Different Strengths in Risk Stratification of Thyroid Nodules. Eur Radiol (2020) 30:3793–802. doi: 10.1007/s00330-020-06722-y
8. Hang Q, Ma J, Sun W, Zhang L. Comparison Of Diagnostic Performance Between The American College of Radiology Thyroid Imaging Reporting And Data System And American Thyroid Association Guidelines: A Systematic Review. Endocr Pract (2020) 26:552–63. doi: 10.4158/EP-2019-0237
9. Kwak JY, Han KH, Yoon JH, Moon HJ, Son EJ, Park SH, et al. Thyroid Imaging Reporting and Data System for US Features of Nodules: A Step in Establishing Better Stratification of Cancer Risk. Radiology (2011) 260:892–9. doi: 10.1148/radiol.11101206
10. Shin JH, Baek JH, Chung J, Ha EJ, Kim JH, Lee YH, et al. Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol (2016) 17:370–95. doi: 10.3348/ kjr.2016.17.3.370
11. Tesser FK, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol (2017) 14:587–95. doi: 10.1016/j.jacr.2017.01.046
12. Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasonic Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J (2017) 6:225–37. doi: 10.1159/000478927
13. Zhou J, Yin L, Wei X, Zhang S, Song Y, Luo B, et al. 2020 Chinese Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules: The C-TIRADS. Endocrine (2020) 70:256–79. doi: 10.1007/s12020-020-02441-y
14. Gao L, Xi X, Jiang Y, Yang X, Wang Y, Zhu S, et al. Comparison Among TIRADS (ACR TI-RADS and KWAK- TI-RADS) and 2015 ATA Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules: Comparison Between The American College of Radiology Thyroid Imaging Reporting And Data System And American Thyroid Association Guidelines: A Systematic Review. J Am Coll Radiol (2017) 14:587–95. doi: 10.1016/j.jacr.2017.01.046

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

AZ and PX collected and classified the thyroid nodules. SG, SC and YL followed up the thyroid nodules. QQ and XH compiled and analyzed the data. QQ and AZ wrote the paper. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by Key Research and Development Program of Jiangxi Province (20181BBG70031) and Jiangxi Postgraduate Innovation Foundation (YC2021-B043).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.763897/full#supplementary-material
in the Diagnostic Efficiency of Thyroid Nodules. *Endocrine* (2019) 64:90–6. doi: 10.1007/s12020-019-01843-x

15. Hu EJ, Lim HK, Yoon JH, Steering JH, KH D, Choi M, et al. Primary Imaging Test and Appropriate Biopsy Methods for Thyroid Nodules: Guidelines by Korean Society of Radiology and National Evidence-Based Healthcare Collaborating Agency, *Korean J Radiol* (2018) 19:623–31. doi: 10.3348/kjr.2018.19.4.623

16. Xu T, Gu JY, Ye XH, Xu SH, Wu Y, Shao XY, et al. Thyroid Nodule Sizes Influence the Diagnostic Performance of TIRADS and Ultrasound Patterns of 2015 ATA Guidelines: A Multicenter Retrospective Study. *Sci Rep* (2017) 7:43183. doi: 10.1038/srep43183

17. Park CS, Kim SH, Jung SL, Kang BJ, Kim JY, Choi JJ, et al. Observer Variability in the Sonographic Evaluation of Thyroid Nodules. *J Clin Ultrasound* (2010) 38:287–93. doi: 10.1002/jcu.20689

18. Persichetti A, Di Stasio E, Coccaro C, Graziano F, Bianchini A, Di Donna V, et al. Frasoldati A Et Al: Inter- and Intraobserver Agreement in the Assessment of Thyroid Nodule Ultrasound Features and Classification Systems: A Blinded Multicenter Study. *Thyroid* (2020) 30:237–42. doi: 10.1089/thy.2019.0360

19. Grani G, Lamartina L, Cantisani V, Maranghi M, Lucia P, Durante C: Interobserver Agreement of Various Thyroid Imaging Reporting and Data Systems. *Endocr Connect* (2018) 7:1–7. doi: 10.1530/EC-17-0336

20. Koc AM, Adibelli ZH, Erkul Z, Sahin Y, Dilek I. Comparison of Diagnostic Accuracy of ACR-TIRADS, American Thyroid Association (ATA), and EU-TIRADS Guidelines in Detecting Thyroid Malignancy. *Eur J Radiol* (2020) 133:109390. doi: 10.1016/j.ejrad.2020.109390

21. Schenke S, Klett R, Seifert P, Kreissl MC, Gorges R, Zimny M. Diagnostic Variability in the Sonographic Evaluation of Thyroid Nodules. *World J Surg* (2008) 32(5):747–53. doi: 10.1007/s00268-007-9453-0

22. Moon HJ, Lee HS, Kim EK, Ko SY, Seo JY, Park WJ, et al. Thyroid Nodules <= 5 Mm on Ultrasonography: Are They “Leave Me Alone” Lesions? *Endocrine* (2015) 49:735–44. doi: 10.1007/s12020-015-0526-9

23. Ha EJ, Na DG, Moon WJ, Lee YH, Choi N. Diagnostic Performance of Thyroid Nodule Smaller Than 1.0 Cm: Accuracy of TIRADS Classification System in More Than 1000 Nodules. *Br J Radiol* (2018) 91:20170642. doi: 10.1259/bjr.20170642

24. Hu L, Liu X, Pei C, Xie L, He N. Assessment of Perinodular Stiffness in Differentiating Malignant From Benign Thyroid Nodules. *Endocr Connect* (2021) 10:492–501. doi: 10.1530/EC-21-0034

25. Mendes GF, Garcia MR, Falsarella PM, Rahal A, Cavalcante JF, Nery DR, et al. Fine Needle Aspiration Biopsy of Thyroid Nodule Smaller Than 1.0 Cm: Performance of Different Thyroid Imaging Reporting and Data Systems. *World J Surg* (2021) 11:3604–18. doi: 10.1007/s00268-020-05166-9

26. Xue X, Gu JY, Ye XH, Wu Y, Shao XY, et al. Kwak-TIRADS, EU-TIRADS and ACR TI-RADS for Risk Stratification of Small Thyroid Nodules (<= 10 Mm). *J Clin Med* (2020) 9:236. doi: 10.3390/jcm9010236

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Qi, Zhou, Guo, Huang, Chen, Li and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.